Tags

Type your tag names separated by a space and hit enter

C-Peptide reverses nociceptive neuropathy in type 1 diabetes.
Diabetes 2006; 55(12):3581-7D

Abstract

We examined the therapeutic effects of C-peptide on established nociceptive neuropathy in type 1 diabetic BB/Wor rats. Nociceptive nerve function, unmyelinated sural nerve fiber and dorsal root ganglion (DRG) cell morphometry, nociceptive peptide content, and the expression of neurotrophic factors and their receptors were investigated. C-peptide was administered either as a continuous subcutaneous replacement dose via osmopumps or a replacement dose given once daily by subcutaneous injection. Diabetic rats were treated from 4 to 7 months of diabetes and were compared with control and untreated diabetic rats of 4- and 7-month duration. Osmopump delivery but not subcutaneous injection improved hyperalgesia and restored the diabetes-induced reduction of unmyelinated fiber number (P < 0.01) and mean axonal size (P < 0.05) in the sural nerve. High-affinity nerve growth factor (NGF) receptor (NGFR-TrkA) expression in DRGs was significantly reduced at 4 months (P < 0.01). Insulin receptor and IGF-I receptor (IGF-IR) expressions in DRGs and NGF content in sciatic nerve were significantly decreased in 7-month diabetic rats (P < 0.01, 0.05, and 0.005, respectively). Osmopump delivery prevented the decline of NGFR-TrkA, insulin receptor (P < 0.05), and IGF-IR (P < 0.005) expressions in DRGs and improved NGF content (P < 0.05) in sciatic nerve. However, subcutaneous injection had only marginal effects on morphometric and molecular changes in diabetic rats. We conclude that C-peptide exerts beneficial therapeutic effects on diabetic nociceptive neuropathy and that optimal effects require maintenance of physiological C-peptide concentrations for a major proportion of the day.

Authors+Show Affiliations

Department of Pathology, Scott Hall 9275, 540 E. Canfield Ave., Detroit, MI 48201, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17130507

Citation

Kamiya, Hideki, et al. "C-Peptide Reverses Nociceptive Neuropathy in Type 1 Diabetes." Diabetes, vol. 55, no. 12, 2006, pp. 3581-7.
Kamiya H, Zhang W, Ekberg K, et al. C-Peptide reverses nociceptive neuropathy in type 1 diabetes. Diabetes. 2006;55(12):3581-7.
Kamiya, H., Zhang, W., Ekberg, K., Wahren, J., & Sima, A. A. (2006). C-Peptide reverses nociceptive neuropathy in type 1 diabetes. Diabetes, 55(12), pp. 3581-7.
Kamiya H, et al. C-Peptide Reverses Nociceptive Neuropathy in Type 1 Diabetes. Diabetes. 2006;55(12):3581-7. PubMed PMID: 17130507.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - C-Peptide reverses nociceptive neuropathy in type 1 diabetes. AU - Kamiya,Hideki, AU - Zhang,Weixian, AU - Ekberg,Karin, AU - Wahren,John, AU - Sima,Anders A F, PY - 2006/11/30/pubmed PY - 2007/1/17/medline PY - 2006/11/30/entrez SP - 3581 EP - 7 JF - Diabetes JO - Diabetes VL - 55 IS - 12 N2 - We examined the therapeutic effects of C-peptide on established nociceptive neuropathy in type 1 diabetic BB/Wor rats. Nociceptive nerve function, unmyelinated sural nerve fiber and dorsal root ganglion (DRG) cell morphometry, nociceptive peptide content, and the expression of neurotrophic factors and their receptors were investigated. C-peptide was administered either as a continuous subcutaneous replacement dose via osmopumps or a replacement dose given once daily by subcutaneous injection. Diabetic rats were treated from 4 to 7 months of diabetes and were compared with control and untreated diabetic rats of 4- and 7-month duration. Osmopump delivery but not subcutaneous injection improved hyperalgesia and restored the diabetes-induced reduction of unmyelinated fiber number (P < 0.01) and mean axonal size (P < 0.05) in the sural nerve. High-affinity nerve growth factor (NGF) receptor (NGFR-TrkA) expression in DRGs was significantly reduced at 4 months (P < 0.01). Insulin receptor and IGF-I receptor (IGF-IR) expressions in DRGs and NGF content in sciatic nerve were significantly decreased in 7-month diabetic rats (P < 0.01, 0.05, and 0.005, respectively). Osmopump delivery prevented the decline of NGFR-TrkA, insulin receptor (P < 0.05), and IGF-IR (P < 0.005) expressions in DRGs and improved NGF content (P < 0.05) in sciatic nerve. However, subcutaneous injection had only marginal effects on morphometric and molecular changes in diabetic rats. We conclude that C-peptide exerts beneficial therapeutic effects on diabetic nociceptive neuropathy and that optimal effects require maintenance of physiological C-peptide concentrations for a major proportion of the day. SN - 0012-1797 UR - https://www.unboundmedicine.com/medline/citation/17130507/C_Peptide_reverses_nociceptive_neuropathy_in_type_1_diabetes_ L2 - http://diabetes.diabetesjournals.org/cgi/pmidlookup?view=long&amp;pmid=17130507 DB - PRIME DP - Unbound Medicine ER -